CDKN2A and glioblastoma: These findings highlight CDKN2A as a potential therapeutic target for glioblastoma, as strategies aimed at restoring CDKN2A expression or inhibiting its silencing mechanisms may offer promising avenues for the development of novel treatment approaches.